Guardant Reveal Blood Test Outperforms Standard Staging in Predicting Colon Cancer Recurrence
Event summary
- Guardant Health's Reveal blood test identified a 4-to-6-fold higher rate of disease recurrence or reduced survival in stage III colon cancer patients compared to standard staging.
- The study, published in the Journal of Clinical Oncology, involved over 2,000 patients and found that 20% had detectable circulating tumor DNA (ctDNA) after surgery.
- Higher tumor fraction levels in ctDNA further distinguished patients at the highest risk of early recurrence and worse survival.
- Guardant Reveal's tissue-free approach supports personalized adjuvant treatment and surveillance decisions.
The big picture
This study reinforces the growing role of ctDNA testing in precision oncology, particularly for identifying high-risk patients post-surgery. Guardant Health's Reveal test is positioning itself as a critical tool for personalized treatment decisions, potentially reshaping adjuvant therapy strategies in colon cancer. The findings align with broader industry trends toward liquid biopsy solutions that offer non-invasive, actionable insights for cancer management.
What we're watching
- Clinical Adoption
- How quickly Guardant Reveal integrates into routine postoperative management for colon cancer patients.
- Competitive Positioning
- Whether Guardant can sustain its lead in ctDNA testing as competitors develop similar technologies.
- Regulatory Expansion
- The pace at which Guardant expands Reveal's use cases beyond MRD detection to other solid tumors.
Our editorial coverage:
Related topics